The 5th IVI International Congress: Reproductive Medicine and Beyond by ComtecMed 04-Apr-13 to 06-Apr-13 Seville , SPAIN (GYN - Contraception & Reproductive Health)
2013 AIUM Annual Convention by American Institute of Ultrasound in Medicine 06-Apr-13 to 10-Apr-13 New York (New York Marriott Marquis Hotel) , NY USA (CME - Medical Education)
Manejo clínico y terapéutico de la esterilidad. Segundo curso online by Fundacio Dexeus Salud de la Mujer 09-Apr-13 to 31-May-13 online , SPAIN(gynecology)
Pediatric Nursing: Care of the Hospitalized Child by Continuing Education Inc. 10-Apr-13 to 13-Apr-13 Anaheim (Hyatt Regency Orange County) , CA USA (CME - Obstetrics, Gynecology & Women's Health)
Medicina fetal Curso-Taller. Curso de Nivel I y II de la SESEGO by Fundacio Dexeus Salud de la Mujer 15-Apr-13 to 17-Apr-13 Barcelona (Auditorio Salud de la Mujer Dexeus) , SPAIN (OB - Maternal Fetal Medicine)
Female Urology & Urogynecology Symposium (FUUS) by Quadrant HealthCom, Inc 18-Apr-13 to 20-Apr-13 Las Vegas (ARIA) , NV USA (CME - Obstetrics, Gynecology & Women's Health)
Female Urology and Urogynecology Symposium (FUUS) 2013 by Quadrant HealthCom, Inc 18-Apr-13 to 20-Apr-13 Las Vegas (ARIA) , NV USA (CME - Obstetrics, Gynecology & Women's Health)
This phase I study was undertaken to define the maximum tolerated dose, the dose-limiting toxicity, and the recommended dose of UFT plus leucovorin and vinorelbine in combination treatment of patients with metastatic breast cancer previously treated with one chemotherapy regimen. The... More »
CANTON, Ohio—Neoadjuvant breast cancer therapy research has revealed that “epirubicin has good activity in the neoadjuvant setting and was associated with prolonged survival in four studies, although this remains to be confirmed,” Terry Mamounas, MD, stated. Dr. Mamounas, Medical Director at Aultman... More »
NEW YORK—“The number one question that I used to get as a clinician taking care of people with breast cancer and people worried about breast cancer was about hormone replacement therapy. Now, by far, the number one question is about soybeans,” said Larry Norton, MD, chief of Breast Medicine and head... More »
MUNICH, Germany—‘‘Epirubicin-containing regimens significantly prolong relapse-free and overall survival rates compared with standard regimens” for treating breast cancer, Michael Untch, MD, reported at a clinical investigators’ workshop. ‘‘The dose-response relationship for epirubicin,” he... More »
ROCHESTER, Minnesota—Researchers have begun to suspect that estrogen might be important not only for its receptor-mediated effects but also because it may exert genotoxic effects, reported James N. Ingle, MD. “There is evidence that estrogen genotoxicity may play a role in breast cancer development.... More »
PISA, Italy—‘‘Anthracycline/taxane combinations given upfront should be the new standard of care for metastatic breast cancer,” Pierfranco Conte, MD, said at a clinical investigators’ workshop sponsored by the University of Texas M. D. Anderson Cancer Center and Pharmacia Oncology. Dr. Conte is... More »
Adjuvant chemotherapy represents a significant advance in the management of early-stage breast cancer and, as such, has saved many lives. Worldwide, adjuvant chemotherapy has benefitted all groups tested, including More »
TORONTO—Epirubicin (Ellence) and doxorubicin (Adriamycin) in combination regimens for adjuvant treatment of breast cancer will be compared in a major randomized controlled trial sponsored by the National Cancer Institute of Canada (NCIC), according to Maureen Trudeau, MD, head of systemic therapy at... More »
Glioblastoma multiforme (GBM) cells are characterised by their extreme chemoresistance. The activity of multiple-drug resistance (MDR) transporters that extrude antitumor drugs from cells plays the most important role in this phenomenon. To date, the mechanism controlling the expression and activity of MDR transporters is poorly understood. Activity of the enzyme ecto-5'-nucleotidase (CD73) in tumor cells, which hydrolyses AMP to adenosine, has been linked to immunosuppression and prometastatic effects in breastcancer and to the proliferation of glioma cells. In this study, we identify a high expression of CD73 in surgically resected samples of human GBM. In primary cultures of GBM, inhibition of CD73 activity or knocking down its expression by siRNA reversed the MDR phenotype and cell viability was decreased up to 60% on exposure to the antitumoral drug vincristine. This GBM chemosensitization was caused by a decrease in the expression and activity of the multiple drug associated
Night work involving disruption of circadian rhythm was suggested as a possible cause of breastcancer. We examined the role of night work in a large population-based case-control study carried out in France between 2005 and 2008. Lifetime occupational history including work schedules of each night work period was elicited in 1,232 cases of breastcancer and 1,317 population controls. Thirteen percent of the cases and 11% of the controls had ever worked on night shifts (OR = 1.27 [95% confidence interval = 0.99-1.64]). Odds ratios were 1.35 [1.01-1.80] in women who worked on overnight shifts, 1.40 [1.01-1.92] in women who had worked at night for 4.5 or more years, and 1.43 [1.01-2.03] in those who worked less than three nights per week on average. The odds ratio was 1.95 [1.13-3.35] in women employed in night work for >4 years before their first full-term pregnancy, a period where mammary gland cells are incompletely differentiated and possibly more susceptible to circadian disruption
Tissue polypeptide-specific antigen (TPS), a specific epitope structure of a peptide in serum associated with human cytokeratin 18, is linked to the proliferative activity of tumors. Here, we aimed to identify the association between the preoperative serum TPS level and outcome in breastcancer patients. We assayed preoperative serum TPS levels in 1,477 breastcancer patients treated between June 2000 and December 2006. The TPS level was measured with a one-step solid phase radiometric sandwich assay detecting the M3 epitope on cytokeratin 18 fragments. The cutoff value was 80 U/L. Among the 1,477 breastcancer patients examined, preoperative serum TPS level was elevated (>80 U/L) in 290 patients (19.6%). Age (>45 years), tumor size (>2 cm), nodal metastasis, negative progesterone receptor and human epidermal growth factor receptor 2 were associated with elevated TPS. Evidence of recurrence was observed in 229 patients (15.6%). Elevated TPS was associated with poor disease-free
We previously reported an inverse association between sleep duration and breastcancer risk in the prospective, population-based Singapore Chinese Health Study (SCHS) cohort (Wu et al., Carcinogenesis 2008;29:1244-8). Sleep duration was significantly positively associated with 6-sulfatoxymelatonin (aMT6s) levels determined in a spot urine, but aMT6s levels in breastcancer cases were lacking (Wu et al., Carcinogenesis 2008;29:1244-8). We updated the sleep duration-breastcancer association with 14 years of follow-up of 34,028 women in the SCHS. In a nested case-control study conducted within the SCHS, randomly timed, prediagnostic urinary aMT6s concentrations were compared between 248 incident breastcancer and 743 individually matched cohort controls. Three female controls were individually matched to each case on age at baseline interview (within 3 years), dialect group, menopausal status, date of baseline interview (within 2 years), date of urine sample collection (within 6 months)
Cancer of unknown primary site (CUP) is a fatal cancer ranking among the five most common cancer deaths. CUP is diagnosed through metastases, which are limited to lymph nodes in some patients. Cause-specific survival data could guide the search for hidden primary tumors and help with therapeutic choices. The CUP patients were identified from the Swedish Cancer Registry between 1987 and 2008; 1,444 patients had only lymph node metastasis of defined histology (adenocarcinoma, squamous cell or undifferentiated). Site-specific cancer deaths were analyzed by lymph node location and histology. Kaplan-Meier survival curves were compared with metastatic primary cancer at related sites. Among the patients with metastasis to head and neck lymph nodes, 117 (59.1% of the specific cancer deaths) died of lung tumors. Patients with axillary lymph node metastasis died of lung and breast tumors in equal proportions (40.2% each). Also, squamous cell CUP in head and neck lymph nodes was mainly
Morcellation of the Uterus is an oncologically flawed and dangerous practice. It is incredible that the gynecological community is accepting the practice as safe. For example, the incidence of occult leiomyosarcoma is 1/400 in women who undergo hysterectomy for presumed benign fibroid disease. Morcellation leads to conversion of an early stage, contained and potentially curable uterine cancers to a deadly stage 4 cancer; that is, sarcomatosis or carcinomatosis. Morcellation is virtually never part of the informed consent process. And even if it was, the incidence of occult uterine malignancy makes it a disastrous and unethical technique. Please refer to the following link to a petition to place an immediate moratorium on this terrible practice. It is your ethical responsibility to explore this issue and help stop it: https://www.change.o...ve-hysterectomy
Has anyone tried FetalGrowth app (App Store for iPhone/iPad) ? I'm interested in using a simple and handy tool to calculate fetal percentiles, and I came across this app, which seems it does the job (plots growth charts, as well). I haven't seen anything else, besides this app, so I was wondering if there are people who have already tried it.
’Scientists have somehow missed definitions of gender in human beings,” states Dr. Makarand Fulzele. Insights gained from years of practice as surgeon makes him wonder if indeed we have overlooked facts staring in our face. Nature has a tendency to hide many secrets but at the same time it provides enough clues to unravel its mysteries. Dr. Fulzele picks up loose threads from life to stitch together the theory that man is an extension of woman in his new book, “Man Is the Extension of Woman: Know the Ultimate Truth about Yourself” (published by iUniverse). Dr. Fulzele’s book explores similarities between men and women against the backdrop of their genetic differences, physical variations, and emotional and intellectual dissimilarities. Dr. Fulzele who is a successful surgeon further explains in his book: The main hypothesis I discuss in this book is that, if a woman lives long enough she will be converted into a man physically. A similar thing can also be stated about man. It is wrong to categorize humankind into two genders as it implicates that they are extremely dissimilar and physically opposite to each other. I try to prove that man and woman are just two different stages of one developmental process. And physically they are very similar. The ideas presented may sound unconventional but Dr. Fulzele implores readers to consider his point of view with an open mind. “Your world will not change if you do not agree with me. But if you agree with me, how does it change your world? If more people agree with you and me, how does it change our world? The possibilities are limitless.” About the Author Dr. Makarand Fulzele is a successful surgeon and medical superintendent of a government hospital in Mumbai. He enjoys tapping into hidden and mysterious regions of the human mind, where many strange thoughts occur and get ignored. He is also the author of “Rainbow,” a book similarly dedicated to the spirit of light.
Nasal Surgery is the most common approach of open rhinoplasty. It is performed through incisions on the inside of the nose, as well as a single 4 or 5 mm external incision on the undersurface of the narrow area between the two nostrils. It is a reliable procedure that can dramatically improve the appearance and balance of your face.To know more..
To all the members of OB-GYN-L… Thank you for coming! I’m thrilled that you’ve decided to check out the new Forum site, and look forward to reading about what’s on your mind.
If you’re new to the ObGyn.net community... welcome aboard! You’ve just joined an outstanding group of physicians and health care professionals who have been sharing information, answering questions, and building professional relationships via the site’s listserv for nearly 20 years.
Feel free to poke around on the site to get a feel for things, or take a look at the Help Topics page for instructions on how to use the different features of the site.
A few quick tips: For those of you who like getting new Forum messages delivered directly to your inbox, the first thing you’ll want to do is click on the ‘Follow this forum’ button on the main page. You’ll have the option of getting notifications immediately, as a daily digest, a weekly digest, or only when you’re not online (which is to say, if you’re on the site when someone posts a message, you won’t be notified of it). You won’t be able to post on the site just by replying to the email, but the message will contain a link that takes you directly to the message you’d like to reply to.
You can also follow individual conversations without following the whole list by going into the topic and clicking the ‘Follow this topic’ button next to the title.
Also, in ‘My Profile’ you can:
Enter your professional information, including specialty, subspecialty, and education (by clicking ‘Edit my profile’)
See your activity on the Forum, such as what discussions you have initiated or replied to, content you’ve ‘liked,’ and activity of people you’ve made your friends
In ‘My Settings’ you can:
Add or change your photo
Edit your birthday, gender, interests, location
Create a signature for your posts
Change the types of content you get notifications for, or change the way you receive notifications
If you have questions, feel free to respond to this post or send me a direct message by clicking on the envelope icon.
Many thanks for your interest in the FetalGrowth app, it was a surprise for us to see the post Carlos has started, and those many follow-ups ! We would like to make some comments regarding our app:
Why Fetalgrowth app, in the first place? Most ultrasound equipments that compute fetal weight percentiles and most charts and calculators available on the internet rely on basic statistical models and have quite limited accuracy. This is fine for example in normal pregnancies where say, one chart gives you a figure of 40% ptile while another gives you, 60%. You 'll know you are dealing with a more or less normal fetal weight. But what happens when one calculator gives you 5% and another 25%? You will surely want to rely on a tool as accurate as possible to be certain you deal with a Small for Gestational Age case or not. In such cases Fetalgrowth will be of much help as it is an accurate tool using fully customized statistical models (you will need to input more info but calculation will be more reliable).
Customization is provided for several countries such as Spain, Sweden, Netherlands, Ireland, UK, USA, Australia, etc. If interested to include a model of your country and may provide us with pregnancies statistics for that country, please contact us at firstname.lastname@example.org.
Just to make sure, we will detail a bit what is actually required to add a model for a new country. We need some data (nation-wide statistics) regarding pregnancies in that country. Namely, we need a list of singleton pregnancies and twins pregnancies with the following data (this is the minimum information required):
- Mother's age - Maternal Ethnicity - Maternal Parity - Maternal Height - Maternal Weight at booking - Gestation (weeks,days) - Baby's weight at birth - Fetus Gender
We need to know if the mother suffered certain conditions that could have affected fetal development and if the pregnancy was normal or not.
A minimum of 1000 singleton cases and at least 200 twins cases would be needed to design the statistial model of birthweight and based on this model implement the calculator and growth charts.
It must not have come as a surprise to professional billers and coders that the complexities around OBGYN are beginning to take a toll on OBGYN care providers’ finances. Understanding the complexities of OBGYN, any expert will admit, is not easy as there are various rules as well as exceptions together with multiple codes for a range of medical billing services and phases involved in OBGYN. http://www.medicalbi...x?ArticleId=429
CC is a 31 year old primigravida who was referred for ultrasound at a community hospital due to suspected cardiac anomalies noted on a screening sonogram at her doctor's office. Due to concern about a probable cardiac abnormality an amniocentesis was performed at the local hospital.
Single umbilical artery color doppler, transverse scan of urinary bladder shows single umbilical artery (left), transverse section of umbilical cord showing only two vessels: one vein and one artery (right).
How Physicians Can Manage Unexpected Free Time Jennifer Frank, MD, October 22, 2013 Whether you have an unexpected patient no-show, or two hours before bed, figuring out how to spend spurts of free time can be a work-life balance stressor.